Precise has retained Carnegie Investment Bank AB as placing agents in a private placement of New Shares directed towards international institutional investors and qualified investors in Sweden (the "Private Placement").
The price of the New Shares will be determined through an accelerated book-building procedure, and the New Shares will be admitted to trading on NASDAQ OMX Stockholm following their issuance and registration. The placing will start immediately. The minimum order in the Private Placement has been set to the number of shares that equals an aggregate purchase price of at least the equivalent of SEK 1,000,000. Pricing and allocation of the Private Placement is expected to take place before beginning of trading on NASDAQ OMX Stockholm at 09:00 CET on September 6, 2013. The total amount of New Shares to be offered in the Private Placement will be determined in the book-building process.
The proceeds from the Private Placement will further enhance the company's working capital related to growth and order financing.
The Private Placement is subject (inter alia) to resolution by the Board of Directors of Precise, pursuant to the authorization given by the 2013 annual general meeting, to issue New Shares following close of the Private Placement book-building procedure.
The above information has been made public in accordance with the Securities Market Act. The information was submitted for publication at on 6.35 pm CET September 5, 2013.
The publication or distribution of this press release may in certain jurisdictions be subject to restriction by law, and persons in the jurisdictions where this press release has been published or distributed should inform themselves of and follow such legal restrictions. This press release does not contain or constitute an invitation or offer to acquire, subscribe to or otherwise trade with shares, subscription rights or other securities in Precise Biometrics.
This press release may not be made public, published or distributed, either directly or indirectly in the United States, Canada, Japan, New Zealand, South Africa, Australia or any other country where such procedures are subject in full or in part to legal restrictions. Nor may the information in this press release may not be communicated, reproduced or presented in any way that is in conflict with such restrictions. Failure to follow this instruction may involve a breach of the United States Securities Act from 1933 ("Securities Act") or applicable laws in other jurisdictions.
This press release may contain forward-looking statements. When used in this press release, words such as "evaluate", "expect" and "intend" are intended to identify forward-looking statements. They may involve risks and uncertainties, including product demand and market acceptance, the effect of economic conditions, the impact of competitive products and pricing, foreign currency exchange rates and other risks. These forward-looking statements reflect the views of the management as of the date made with respect to future events and are subject to risks and uncertainties. All of these forward-looking statements are based on estimates and assumptions made by the management and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements. Precise Biometrics disclaims any intention or obligation to update these forward-looking statements.